What are the main functions and effects of sunitinib? Targeted therapy and indication analysis
Sunitinib : is a multi-target tyrosine kinase inhibitor (TKI) that is widely used in targeted therapy of tumors. Its main mechanism of action is to inhibit key signaling pathways such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), thereby blocking tumor angiogenesis, reducing nutrient supply, and directly inhibiting the proliferation and survival of tumor cells. This mechanism enables it to exhibit significant efficacy in the treatment of various malignant tumors. Indications for sunitinib include the following:
1. Advanced renal cell carcinoma (RCC): Sunitinib is one of the first-line standard therapies for the treatment of advanced renal cell carcinoma, especially for locally advanced or metastatic disease. It can effectively delay disease progression and improve progression-free survival (PFS) and overall survival (OS).
2. Gastrointestinal stromal tumor (GIST): For patients with GIST who are resistant or intolerant to imatinib (Gleevec), sunitinib is an important second-line treatment option. It inhibits KIT and PDGFRA mutations that drive GIST development, thereby controlling tumor growth.
3. Pancreatic neuroendocrine tumors (pNET): Sunitinib is also one of the targeted drugs for the treatment of advanced pancreatic neuroendocrine tumors, which can effectively improve the progression-free survival of patients and reduce tumor-related symptoms.
Sunitinib may cause side effects such as hypertension, fatigue, hand-foot syndrome, and gastrointestinal discomfort during treatment. Therefore, patients need to use the medication scientifically under the guidance of a doctor and regularly monitor relevant indicators to ensure efficacy and safety. For patients with renal cancer, GIST and pNET, targeted therapy with sunitinib provides important treatment opportunities, improves long-term survival rates and enables advanced patients to achieve a better quality of life.
Reference materials:https://www.sutent.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)